Patients With Ovarian Cancer Treated With FDA-Approved PARP Inhibitors Had Significant Differences In Incidence Of Clinically Relevant AEs

Oncology Nursing News (6/14, Fischer) reported, “Patients with ovarian cancer treated with FDA-approved PARP inhibitors had significant differences in the incidence of clinically relevant adverse events (AEs), according to results of a real-world analysis.” The findings were presented at the 2022 ASCO Annual Meeting.